RT @Berninini: @Plenary_Session @RBeechPharmD @VPrasadMDMPH https://t.co/tWd13prGs2 https://t.co/SfH4E2tNPQ - Here are a few focused on old…
@Plenary_Session @RBeechPharmD @VPrasadMDMPH https://t.co/tWd13prGs2 https://t.co/SfH4E2tNPQ - Here are a few focused on older pts!
RT @Berninini: @MDPhD10 @dgermain21 Not many options if *very* unfit 😕FLAG would be my typical choice - very well tolerated even in octogen…
@MDPhD10 @dgermain21 Not many options if *very* unfit 😕FLAG would be my typical choice - very well tolerated even in octogenarians https://t.co/tWd13prGs2
RT @Berninini: Similar to our FLAG data! Purine analogue-AraC combinations 👍🏼 https://t.co/1RZkOjzhVN and https://t.co/fV5o7Twnd0 #Leusm ht…
Similar to our FLAG data! Purine analogue-AraC combinations 👍🏼 https://t.co/1RZkOjzhVN and https://t.co/fV5o7Twnd0 #Leusm
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. https://t.co/5X6lkY0hbQ
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. https://t.co/xuy96fc02o #leukemia https://t.co/qaiaj2N9vg
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. https://t.co/5X6lkY0hbQ